MAPK8 and melanoma: Melanoma cells treated with the PAK inhibitor PF-3758309 displayed increased activation of JNK, β-catenin, and the mTOR signaling pathway and shRNA-mediated gene silencing JNK and β-catenin further decreased melanoma cell viability [176].